Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• LiuKJGuanZZLiangYA double-blind, randomized phase II study of dicycloplatin plus paclitaxel versus carboplatin plus paclitaxel as first-line therapy for patients with advanced non-small-cell lung cancersArch Med Sci201410471772425276156
   PubMed Web of Science ®Google Scholar
• StinchcombeTESocinskiMACurrent treatments for advanced stage non-small cell lung cancerProc Am Thorac Soc20096223324119349493
   PubMedGoogle Scholar
• HottaKMatsuoKUeokaHKiuraKTabataMTanimotoMAddition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trialsAnn Oncol200415121782178915550583
   PubMed Web of Science ®Google Scholar
• SchillerJHHarringtonDBelaniCPComparison of four chemotherapy regimens for advanced non-small-cell lung cancerN Engl J Med20023462929811784875
   PubMed Web of Science ®Google Scholar
• OheYOhashiYKubotaKRandomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in JapanAnn Oncol200718231732317079694
   PubMed Web of Science ®Google Scholar
• Perez-SolerRChachouaAHammondLADeterminants of tumor response and survival with erlotinib in patients with non-small-cell lung cancerJ Clin Oncol200422163238324715310767
   PubMed Web of Science ®Google Scholar
• KrisMGNataleRBHerbstRSEfficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trialJAMA2003290162149215814570950
   PubMed Web of Science ®Google Scholar
• CohenMHGootenbergJKeeganPPazdurRFDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancerOncologist200712671371817602060
   PubMed Web of Science ®Google Scholar
• FerraraNRole of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implicationsSemin Oncol200229suppl 16101412516033
   PubMed Web of Science ®Google Scholar
• BergersGBenjaminLETumorigenesis and the angiogenic switchNat Rev Cancer20033640141012778130
   PubMed Web of Science ®Google Scholar
• Jenab-WolcottJGiantonioBJBevacizumab. current indications and future development for management of solid tumorsExpert Opin Biol Ther20099450751719344286
   PubMed Web of Science ®Google Scholar
• WillettGGBoucherYdi TomasoEDirect evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerNat Med200410214514714745444
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
   PubMed Web of Science ®Google Scholar
• ReckMvon PawelJZatloukalPPhase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAilJ Clin Oncol20092781227123419188680
   PubMed Web of Science ®Google Scholar
• ReynoldsCBarreraDJotteRPhase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancerJ Thorac Oncol20094121537154319887966
   PubMed Web of Science ®Google Scholar
• CrinòLDansinEGarridoPSafety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 studyLancet Oncol201011873374020650686
   PubMed Web of Science ®Google Scholar
• NihoSKunitohHNokiharaHRandomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non squamous non-small-cell lung cancer. JO19907 Study GroupLung Cancer201276336236722244743
   PubMed Web of Science ®Google Scholar
• ZhouCWuYLChenGBEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancerJ Clin Oncol201533192197220426014294
   PubMed Web of Science ®Google Scholar
• RoodhartJMHeHDaenenLGNotch1 regulates angio-supportive bone marrow-derived cells in mice: relevance to chemoresistanceBlood2013122114315323690447
   PubMed Web of Science ®Google Scholar
• Volk-DraperLHallKGriggsCPaclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent mannerCancer Res201474195421543425274031
   PubMed Web of Science ®Google Scholar
• ScagliottiGVParikhPvon PawelJPhase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancerJ Clin Oncol200826213543355118506025
   PubMed Web of Science ®Google Scholar
• MirOBoudou-RouquettePGirouxJPemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancerLung Cancer201277110410922364783
   PubMed Web of Science ®Google Scholar
• BarlesiFScherpereelARittmeyerARandomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089)J Clin Oncol201331243004301123835708
   PubMed Web of Science ®Google Scholar
• HiraiFSetoTInamasuEFeasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancerOncol Lett2015962577258226137109
   PubMed Web of Science ®Google Scholar
• CamidgeDRKonoSALuXAnaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexedJ Thorac Oncol20116477478021336183
   PubMed Web of Science ®Google Scholar